T-cell receptor beta chain (TCRB) (TCRB)

The T-cell receptor beta chain (TCRB) is a fundamental component of the alpha-beta T-cell receptor complex, which is expressed on the surface of the majority of T-lymphocytes. Its primary role is to recognize and bind to antigenic peptides presented by major histocompatibility complex (MHC) molecules, thereby initiating the signaling pathways required for T-cell activation and the adaptive immune response (StatPearls, NBK537184). The TCRB chain is characterized by its genetic diversity, generated through V(D)J recombination, and its two distinct constant regions, TRBC1 and TRBC2, which are expressed in a mutually exclusive manner on individual T-cells (UniProt, P01850). This unique expression pattern makes TCRB a precise target for treating T-cell malignancies, such as T-cell lymphomas, by allowing for the selective depletion of the malignant clone while sparing the healthy T-cell compartment (Nature Medicine, PMID: 29233929). Beyond oncology, TCRB is involved in the pathogenesis of autoimmune diseases where T-cells inappropriately target self-antigens, and it is a key focus for TCR-engineered T-cell (TCR-T) therapies designed to treat various solid tumors (NCBI Gene, 6957). Therapeutic interventions targeting TCRB must carefully manage risks such as cytokine release syndrome and potential immunodeficiency resulting from extensive T-cell depletion.

Other names

TRBT-cell antigen receptor betaTRBC1TRBC2T-cell receptor beta locus

TCR-T therapies utilize engineered T-cell receptors to recognize specific peptide-MHC complexes on tumor cells, leading to T-cell activation and tumor lysis. Monoclonal antibodies or CAR-T cells targeting the TRBC1 or TRBC2 constant regions allow for the selective depletion of malignant T-cell clones while preserving a portion of the healthy T-cell population (Nature Medicine, PMID: 29233929).